Clinical Trials Logo

Filter by:
NCT ID: NCT02827487 Recruiting - Pain Clinical Trials

Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion

IUD
Start date: July 1, 2016
Phase: Phase 4
Study type: Interventional

Two hundred and ten women requesting IUD insertion will be randomly divided into three equal groups. To ensure blinding the double dummy technique will be used in which group 1 will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally in addition to a placebo similar to Celecoxib, group 2 will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to Tramadol, and group 3 will received a placebo similar to Tramadol in addition to a placebo similar to Celecoxib. All the drugs will be given 2 hour before the procedure. After insertion of the IUD the women's pain perception will be assessed using a visual analogue scale (VAS) graduated from zero to 10 with zero corresponding to no pain and 10 corresponding to the worst possible pain.

NCT ID: NCT02826447 Recruiting - Clinical trials for Exposure to Hepatitis C Virus

Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C

IMMHoTHep
Start date: February 21, 2017
Phase: N/A
Study type: Observational [Patient Registry]

This project is a prospective observational cohort study to quantify the risk of acquiring Hepatitis C virus (HCV) infection for patients and healthcare workers in Ain Shams University Teaching Hospital, Cairo, Egypt through: 1) identifying typical patient trajectories within the hospital; and 2) assessing the ward-specific risk based on the type and number of procedures performed and the prevalence of HCV viremia in patients within each ward.

NCT ID: NCT02823080 Recruiting - Infertility Clinical Trials

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Start date: October 2014
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate safety and efficacy of 3-day cetrotide therapy started on day of oocyte retrieval (Day-0) in women at high-risk for development of ovarian hyperstimulation syndrome (OHSS) after gonadotropin- releasing hormon agonist induction protocol. Patients & Methods: Forty-eight women fulfilling inclusion criteria underwent ultrasound scanning for maximal ovarian diameter (MOD) estimation and ascites grading. Patients underwent embryo freezing, but study group received 3-day Cetrotide sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites grading were re-evaluated on Day-3, 6 and 8

NCT ID: NCT02822885 Recruiting - Clinical trials for Postmenopausal Bleeding

Uterine Artery and Spiral Artery Doppler Parameters in Patients With Postmenopausal Bleeding

Start date: January 2014
Phase: N/A
Study type: Observational [Patient Registry]

This study was to investigate the diagnostic value of ultrasonography and blood flow measurements in uterine arteries and spiral arteries by transvaginal color Doppler ultrasonography in the detection of the endometrial pathology in women with postmenopausal bleeding.

NCT ID: NCT02816957 Recruiting - Clinical trials for Nigella Sativa With Beta Thalassemia Major

Benefits of Nigella Sativa in Children With Beta Thalassemia Major

Nigella
Start date: June 2016
Phase: Early Phase 1
Study type: Interventional

Evaluate the therapeutic effects health benefits, and immunological effect of Nigella sativa in children with beta thalassemia major.

NCT ID: NCT02816489 Recruiting - Clinical trials for Apical Root Resorption

Labial Alveolar Bone Thickness and Apical Root Resorption Changes Associated With Self-ligating Versus Conventional Brackets

Start date: May 2016
Phase: N/A
Study type: Interventional

Labial alveolar bone thickness and apical root resorption changes associated with self-ligating versus conventional brackets. The aim of this study will be to compare labial alveolar bone thickness and apical root resorption changes associated with self-ligating versus conventional brackets.

NCT ID: NCT02803476 Recruiting - Insulin Resistance Clinical Trials

Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?

Start date: March 2016
Phase: N/A
Study type: Observational

The primary aim of the current study is to clarify whether serum vitamin D levels [25(OH)D3] have a temporal association with insulin resistance and/or insulin sensitivity in PCOS women versus healthy ones. To achieve this aim, the investigators will conduct a prospective observational study involving obese and lean PCOS women in comparison to obese and lean healthy subjects living in Cairo, Egypt.

NCT ID: NCT02802215 Recruiting - Clinical trials for Polycystic Ovary Syndrome

Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome

MGDPCOS
Start date: January 2016
Phase: Phase 2/Phase 3
Study type: Interventional

Randomized, placebo controlled clinical trial that evaluate the role of taking metformin therapy during pregnancy in women with polycystic ovarian syndrome(PCOS) in reducing the development of gestational diabetes(GDM) and improving pregnancy outcomes.

NCT ID: NCT02799316 Recruiting - Hepatitis B Clinical Trials

Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?

Start date: June 2016
Phase: N/A
Study type: Interventional

Hepatitis B virus (HBV) infection is a challenging health problem. According to the World Health Organization, an estimated 240 million individuals (3.7%) suffered from chronic HBV infection worldwide. After acute hepatitis B virus (HBV) infection, the disappearance of hepatitis B surface antigen (HBsAg) had generally been believed to signify viral elimination. However, it now becomes clear that those subjects may have occult HBV infection which is defined as the presence of HBV DNA in the liver in the absence of HBsAg in the serum. Occult HBV infection usually accompanies antibody against hepatitis B core antigen (anti-HBc) and/or antibody against HBsAg (anti-HBs), but some cases might not have these serological markers (seronegative occult HBV infection) .

NCT ID: NCT02797782 Recruiting - Clinical trials for Hepatitis B Vaccines

Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt

Start date: June 2016
Phase: N/A
Study type: Observational

More than two billion individuals have serological evidence of hepatitis B virus (HBV) infection worldwide. Of these, 240 million are chronic carriers and approximately 786,000 hepatitis B related deaths occur annually. Currently available hepatitis B vaccines are extremely safe and have an efficacy of >90 percent against all HBV serotypes and genotypes. Thus, HBV infection can potentially be eradicated through global vaccination. A positive immune response to the vaccine is defined as the development of hepatitis B surface antibody (anti-HBs) at a titer of >10 mIU/mL. Although anti-HBs titers decrease with time, the duration of protection is long. Protection has been estimated to persist for up to 22 years after the primary vaccination schedule. Protection from clinical disease, despite declining or even undetectable anti-HBs levels, is probably due to the priming of memory cells, which are capable of eliciting an anamnestic response when challenged. This is supported by the rapid increases in anti-HBs titers in previously vaccinated individuals who administered booster injections.